ZOE CECILE BURGER
Prescription History 1134815491
Student in an Organized Health Care Education/Training Program in New Haven, CT

NPI Status: Active since April 11, 2023

Contact Information

20 YORK ST
NEW HAVEN, CT
ZIP 06510
Phone: (203) 688-4242

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for ZOE CECILE BURGER, an active Student in an Organized Health Care Education/Training Program specialist practicing in New Haven, CT. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 11 documented patient claims. Among these therapy options, the most frequently utilized medication is Ozempic, which accounts for 11 claims alone.

Medication Index

No matching medications currently found on file.

Ozempic

Generic Formulation: SemaglutideSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 11
30-Day Fills 12.8
Days Supply 336
CT State Average Benchmarks
Peer Average Claims47.0
Peer Average 30-Day Fills76.9
Peer Average Days Supply2,254
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 76.6% less volume than the regional standard for practitioners inside CT. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $13,283.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,207.57

State Avg Cost Per Claim

$1,525.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Semaglutide is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes. Controlling high blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems. Semaglutide is also used in people with type 2 diabetes and heart disease to lower the risk of death from heart attack or stroke. Semaglutide is similar to a natural hormone in your body (incretin). It works by causing insulin release in response to high blood sugar (such as after a meal) and decreasing the amount of sugar your liver makes. If you use insulin, semaglutide is not a substitute for insulin treatment.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like ZOE CECILE BURGER provides transparency into local medical care patterns within New Haven, CT.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Student in an Organized Health Care Education/Training Program** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.